Tick-borneencephalitis Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchTick-borne encephalitis MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:17 Apr 2023Last updated:28 Apr 2023SummaryTick-borne encephalitis (TBE) occurs throughout the northern hemisphere, and mirrors the geographical
The risk of tick-borneencephalitis virus transmission via substances of human origin The risk of tick-borneencephalitis virus transmission via substances of human origin Skip to main content Global Navigation * Other sites * ECDC * European Antibiotic Awareness Day * ESCAIDE - Scientific conference * Eurosurveillance journal * EVIP - Vaccination portal European Centre for Disease Prevention - podcast 1. Home 2. The risk of tick-borneencephalitis virus transmission via substances of human origin The risk of tick-borneencephalitis virus transmission via substances of human originAssessment 2 Oct 2024 Cite: Citation Link European Centre for Disease Prevention and Control. The risk of tick-borneencephalitis virus transmission via substances of human origin. Stockholm: ECDC; 2024 Copy citation
Tick-borneencephalitis: epidemiology, diagnosis and prevention Skip to main contentCookies on GOV.UKWe use some essential cookies to make this website work.We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.We also use cookies set by other sites to help us deliver content from their services.Accept additional cookiesReject additional cookiesView cookies GOV.UKNavigation menuMenuSearch GOV.UKHomeHealth and social carePublic healthHealth protectionInfectious diseasesGuidanceTick-borne encephalitis: epidemiology, diagnosis and preventionAdvice for health professionals on tick-borneencephalitis (TBE) including symptoms, diagnosis and epidemiology.From:UK Health Security AgencyPublished6 August 2019Last updated25 April 2023
No detection of tick-borneencephalitis virus RNA in blood, urine or saliva of hospitalised immunocompetent tick-borneencephalitis patients. Tick-borneencephalitis (TBE) is usually diagnosed based on the presence of TBE virus (TBEV)-specific IgM and IgG antibodies in serum. However, antibodies induced by vaccination or cross-reactivity to previous flavivirus infections may result in false
Seroprevalence of tick-borneencephalitis virus and vaccination coverage of tick-borneencephalitis, Sweden, 2018 to 2019. BackgroundIn Sweden, information on seroprevalence of tick-borneencephalitis virus (TBEV) in the population, including vaccination coverage and infection, is scattered. This is largely due to the absence of a national tick-borneencephalitis (TBE) vaccination registry
Prevalence and genetic diversity of tick-borneencephalitis virus in ixodid ticks from specific regions of northwestern Russia. Russia is a country with a high incidence of tick-borneencephalitis (TBE). In northwestern regions of Russia, 110 TBE cases were registered in 2021. The largest numbers of TBE cases were registered in the Arkhangelsk region and St. Petersburg. TBEV seropositivity among
Phylogenetic characterisation of tick-borneencephalitis virus from Lithuania. The Baltic states are the region in Europe where tick-borneencephalitis (TBE) is most endemic. The highest notification rate of TBE cases is reported in Lithuania, where the incidence of TBE has significantly increased since 1992. A recent study reported 0.4% prevalence of TBE virus (TBEV) in the two most common tick
Tick-borneencephalitis infections without CNS involvement: An observational study in Latvia, 2007-2022. Tick-borneencephalitis (TBE) is a human viral infectious disease involving the central nervous system (CNS). It is caused by the tick-borneencephalitis virus (TBEV). At present, there is very limited information regarding the clinical importance and health burden of TBE infections without
Tick-borneencephalitis: from tick surveillance to the first confirmed human cases, the United Kingdom, 2015 to 2023. BackgroundTick-borne encephalitis virus (TBEV) is a flavivirus spread by ticks and can cause tick-borneencephalitis (TBE) in humans. Previously, TBE has been reported in returning travellers in the United Kingdom (UK), but in 2019 and 2020, two probable cases of TBE acquired
Development and characterization of chimera of yellow fever virus vaccine strain and Tick-Borneencephalitis virus. Tick-borneencephalitis virus (TBEV) is one of the most threatening pathogens which affects the human central nervous system (CNS). TBEV circulates widely in Northern Eurasia. According to ECDC, the number of TBE cases increase annually. There is no specific treatment for the TBEV
Tick-BorneEncephalitis, Lombardy, Italy. Tick-borneencephalitis was limited to northeast portions of Italy. We report in Lombardy, a populous region in the northwest, a chamois displaying clinical signs of tickborne encephalitis virus that had multiple virus-positive ticks attached, as well as a symptomatic man. Further, we show serologic evidence of viral circulation in the area.
Tick-borneencephalitis virus transmitted singly and in duo with Borrelia burgdorferi sensu lato and Anaplasma phagocytophilum bacteria by ticks as pathogens modifying lipid metabolism in human blood. Ticks are vectors of various pathogens, including tick-borneencephalitis virus causing TBE and bacteria such as Borrelia burgdorferi sensu lato and Anaplasma phagocytophilum causing e.g. viral
Differential susceptibility of geographically distinct Ixodes ricinus populations to tick-borneencephalitis virus and louping ill virus. Tick-borneencephalitis virus (TBEV) is an emerging pathogen in the Netherlands. Multiple divergent viral strains are circulating and the focal distribution of TBEV remains poorly understood. This may, however, be explained by differences in the susceptibility
The structure of inactivated mature tick-borneencephalitis virus at 3.0 Å resolution. Tick-borneencephalitis virus (TBEV) causes a severe disease, tick-borneencephalitis (TBE), that has a substantial epidemiological importance for Northern Eurasia. Between 10,000 and 15,000 TBE cases are registered annually despite the availability of effective formaldehyde-inactivated full-virion vaccines due
A combined cross-sectional analysis and case-control study evaluating tick-borneencephalitis vaccination coverage, disease and vaccine effectiveness in children and adolescents, Switzerland, 2005 to 2022. BackgroundTick-borne encephalitis (TBE) is a severe, vaccine-preventable viral infection of the central nervous system. Symptoms are generally milder in children and adolescents than in adults
Autoantibodies neutralizing type I IFNs underlie severe tick-borneencephalitis in ∼10% of patients. Tick-borneencephalitis (TBE) virus (TBEV) is transmitted to humans via tick bites. Infection is benign in >90% of the cases but can cause mild (<5%), moderate (<4%), or severe (<1%) encephalitis. We show here that ∼10% of patients hospitalized for severe TBE in cohorts from Austria, Czech
Tick-borneEncephalitis Clinical Characteristics in Adult Patients: A 10-year Retrospective Study in Stockholm, Sweden. The incidence of Tick-borneencephalitis (TBE) has increased during the last decades in Europe. Our aim was to assess the clinical characteristics and outcome of TBE patients in Region Stockholm, as a high-risk area in Sweden. The notification database at the regional
What makes patients tick? Vaccine preferences against tick-borneencephalitis in four European countries. We explored vaccine motivation and preferences for tick-borneencephalitis (TBE) vaccine attributes among participants in TBE-endemic countries in Europe. An online survey was conducted among the general public in Austria, Germany, Switzerland, and Sweden. Participants were ≥ 18 years old
Poor virus-specific T-cell responses early after tick-borneencephalitis virus infection correlate with disease severity. Tick-borneencephalitis virus (TBEV) infection may cause acute central nervous system inflammation varying in clinical manifestations and severity. A possible correlation of TBEV-specific antibody and cell-mediated immune responses, shortly after infection, with clinical manifestations, severity and long-term outcome has been poorly investigated. In a cohort of thirty early tick-borneencephalitis (TBE) patients, we assessed the magnitude, specificity and functional properties of TBEV-specific T-cell and antibody responses. These responses early during disease were assessed in view of clinical manifestations, severity and long-term outcome. TBEV-specific T-cell responses to C